H uman apolipoprotein (apo) A-IV is a 46-kd
protein that is synthesized primarily in the intestine. 1 ' 2 This apolipoprotein is found in plasma, interstitial fluid, 3 and lymph. 4 In plasma, apoA-IV has been shown to be associated with lipoprotein density fractions as well as in a lipoprotein-free form. 5 However, apoA-IV is easily dissociated from lipoproteins by ultracentrifugation, 6 -7 and therefore, its true plasma distribution among lipoprotein particles remains unknown. By nondenaturing gradient polyacrylamide gel electrophoresis (PAGE), apoA-IV was found to be associated with high density lipoproteins (HDLs) as well as comigratory with albumin. 8 By gel filtration 9 and immunoprecipitation, 10 apoA-IV was shown to be partially associated with HDL. However, all of these techniques could potentially induce perturbations and modify apoA-IV distribution. In addition, apoA-IV is an activator of the plasma enzyme lecithin: cholesterol acyltransferase (LCAT), and cho-lesteryl ester production can also influence the distribution of apoA-IV among lipoproteins.
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Human apoA-IV is an LCAT activator 12 -14 and has a specific binding site on cultured bovine aortic endothelial cells 1516 and cultured mouse Ob 1771 adipose cell surfaces. 1417 Also, reconstituted apoA-IV-dimyristoylphosphatidylcholine (DMPC) complexes, as well as apoA-IV-containing lipoprotein particles that have been isolated from plasma, promote cholesterol efflux from cholesterol-preloaded adipose cells. 17 To gain further insight into the physiological role of apoA-IV, we characterized apoA-IV-containing particles that were isolated from normolipemic human plasma and interstitial fluid by immunoaffinity chromatography.
Methods

Subjects
Fresh blood was collected from six healthy normolipidemic volunteers in tubes containing 1 /xM EDTA, 1.2 g/1 D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone, 0.1 g/1 NaN 3 , 80 mg/1 gentamicin, 10,000 units/1 aprotinin, and 0.15 M NaCl (final concentration). All subjects consented to the procedure after explanation of the purpose of the study. The subjects had fasted for 12 hours. Plasma was collected by centrifugation for 20 minutes at 2,000g at 4°C. Benzamidine was added to the plasma at a final concentration of 1 mM.
Interstitial fluid was collected from 20 healthy normolipidemic subjects by blister suction of forearm skin for 1 hour. The final volume was 6 ml, to which the same inhibitory cocktail was immediately added. All following isolation procedures were performed at 4°C.
Preparation and Purification of Anti-ApoA -I V Antibodies
Antisera to apoA-IV were produced in rabbits by intraperitoneal administration of antigen. The procedure was in accordance with the guidelines of the French Department of Health and Protection of Animals. After precipitation with 40% (wt/vol) (NH 4 ) 2 SO 4 , immunoglobulins were passed over a column of cyanogen bromide-activated Sepharose 4B (Pharmacia) to which human apoA-IV had been coupled. Specific antibodies against apoA-IV were retained in the column and then eluted. First, an elution with 0.1 M acetic acid and 0.15 M NaCl (pH 3.5) was carried out to elute low-affinity antibodies. Second, an elution with 3 M NaSCN was performed to select high-affinity antibodies. Both eluted fractions were immediately dialyzed against 10 mM Tris and 0.15 M NaCl, pH 7.4 (referred to as Tris buffer), and passed over a column to which human apoA-I had been coupled. The unbound fractions were concentrated in Amicon Diaflo cells by using a PM 10 membrane (Amicon, Danvers, Mass.).
Lipoprotein Particle Isolation
Immunosorbents with polyclonal antibodies to apoA-IV (low affinity) and a mixture of monoclonal antibodies to apoA-I (A05-A17-A30) 19 were prepared by coupling the antibodies to cyanogen bromide-Sepharose 4B according to the procedure of the manufacturer (Pharmacia).
Plasma or interstitial fluid was applied at a flow rate of 10 ml/hr in Tris buffer to the anti-apoA-IV immunoaffinity column until the absorption at 280 nm of the eluate was below 0.01 optical density units. After a wash with Tris buffer containing 0.5 M NaCl at a flow rate of 60 ml/hr to remove nonspecifically bound particles, the specifically bound particles, referred to as A-IVLp, were eluted with 3 M NaSCN and immediately filtered through a Sephadex G25 column to remove the thiocyanate.
An aliquot of A-IVLp was applied to an anti-apoA-I immunosorbent under the same conditions. To analyze simple lipoprotein particles and to avoid interactions with apoE and B/E receptors, both retained and unretained fractions were passed through a heparin-Sepharose column in 10 mM Tris (pH 7.4) to remove apoE. No apoE was detectable by a specific apoE enzymelinked immunosorbent assay (ELISA) 20 in the apoA-IV-without-apoA-I-containing lipoproteins (LpA-IV) and in the apoA-IV-with-apoA-I-containing lipoproteins (LpA-I:A-IV) that were obtained after this process. Finally, isolated particles were dialyzed against Tris buffer in a multiple Micro-Prodicon (Bio-Molecular Dynamics) equipped with a PM 10 membrane and filtered through a 0.22-^m Millipore filter.
Analytical Methods
ApoE and apoA-IV phenotypes were determined as described. 2122 Protein content was determined by the method of Lowry et al 23 with bovine serum albumin as the standard. The apolipoprotein concentrations were measured by specific noncompetitive ELISA with monoclonal antibodies to apoA-I, apoA-II, and apoE 24 - 25 and polyclonal antibodies to apoB and apoCIii 26,27 p or apoA-IV determination, the high-affinity apoA-IV antibodies were used at a concentration of 10 mg/ml for plate coating. The same antibodies were conjugated to horseradish peroxidase and used at a 1:5,000 dilution to develop the assay. Calibration curves were prepared with a secondary standard that was determined according to previously described methods. 28 ' 29 Total cholesterol, free cholesterol, triglycerides, and phospholipid contents were measured by using kits from Boehringer Mannheim.
Sodium Dodecyl Sulfate Electrophoresis and Immunoblotting
Protein composition was analyzed by sodium dodecyl sulfate (SDS) 5-19% acrylamide gradient electrophoresis. 30 Eighty micrograms of particle proteins was applied to each sample well. Protein bands were visualized by staining with 0.03% Coomassie blue R-250 that was dissolved in a methanol/acetic acid/water (25:10:45, vol/vol/vol) solvent and destained in the same solvent.
For immunoblotting, proteins were electrophoretically transferred onto nitrocellulose paper at 4°C (30 minutes at 50 V, then 90 minutes at 100 V). The paper was cut into strips and saturated with 1% nonfat dry milk in Tris buffer for 1 hour at room temperature. The strips were incubated with the appropriate antibodies (10 Mg/ml; 1 hour at room temperature for polyclonal antibodies or overnight at 4°C for monoclonal antibodies). After extensive washing with Tris buffer, the strips were incubated with a peroxidase-labeled second antibody for 1 hour at room temperature. Excess labeled antibody was washed away with Tris buffer. Enzymatic activity was developed by addition of 4-chloro-l-naphthol and hydrogen peroxide.
Gel Filtration Chromatography
Particle size was determined by gel filtration chromatography on a fast protein liquid chromatography system (Pharmacia) with a Superose 6B 10/30 column equilibrated in Tris buffer at a flow rate of 0.2 ml/min. All of the isolated lipoproteins were applied to the column, which was calibrated for particle size with very low density lipoprotein (VLDL), low density lipoprotein (LDL), and HDL, 31 as well as the following protein standards: thyroglobulin (17 nm), ferritin (12.2 nm), and bovine serum albumin (7.5 nm). When one sample of each isolated subpopulatiori was applied three times to the column, identical profiles were obtained.
Cellular Cholesterol Efflux Studies
The characterization of the Ob 1771 preadipocyte cell line was reported previously. 32 per milliliter) or only 50 ng of DMPC per milliliter as a control. Cells were washed with phosphate-buffered saline at 4°C to stop the reaction and solubilized in 0.1N NaOH. The remaining cellular cholesterol was determined by radioactivity counting.
LCAT Activity Assay
The LCAT activity of the particles was measured by the method of Chen and Albers. 34 ApoA-I-lecithin [ 14 C]cholesterol complexes were incubated with 20-60 /xg particle protein in a shaking water bath for 15 hours at 37°C. The esterification rate was linear during this time. The reaction was then stopped, and lipids were extracted. Esterified and unesterified cholesterols were separated by thin-layer chromatography, and the radioactivity of the bands was counted.
CET Activity Assay
Cholesterol ester transfer (CET) activity of the particles was measured by the method of Albers et al. 35 In short, isolated particles were mixed with 0.1 mg of a [
14 C]cholesteryl ester-HDL 3 donor and 0.1 mg of an LDL acceptor and incubated at 37°C in a shaking water bath for 5 hours. The reaction was stopped by chilling the tubes on ice. Donor and acceptor lipoproteins were separated by the dextran sulfate/magnesium chloride precipitation procedure.
Results
Plasma Lipid and Apolipoprotein Profile
The general plasma lipid and apolipoprotein profiles of the donor subjects are shown in Table 1 . All subjects were healthy normolipidemic adults with apoE-3/3 and apoA-IV-1/1 phenotypes.
Lipid and Protein Composition of Particles
The lipid and apolipoprotein compositions of the A-IVLp isolated from plasma and interstitial fluid and the LpA-I: A-IV and LpA-IV isolated from plasma are shown in Table 2 . The protein mass ratio between LpA-IV and LpA-I:A-IV is 7:3. All isolated particles have a high protein to lipid ratio and also a high triglyceride content compared with apoA-I-containing particles.
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For A-IVLp and LpA-IV, apoA-IV is the major apolipoprotein, whereas apoA-I is the major apolipoprotein of LpA-I: A-IV. From the composition data of A-IVLp, we estimate that the amount of plasma apolipoproteins associated with apoA-IV is as follows: 0.9±0.4% apoA-I, 2.1 ±1.4% apoA-II, 1.9±0.7% apoB, 0.8±0.4% apoC-III, and 11.7±4.1% apoE. In addition to the assayed apolipoproteins, other proteins could also be detected in the A-IVLp that was isolated from plasma ( Figure 1 ). The diffuse band around 200 kd is apoB-48. ApoD, apoH, proline-rich protein, LCAT, and CET protein were also detected by immunoblotting with specific antisera. In addition, a single band of 59 kd that has not yet been identified was found in the A-IVLp particle.
Gel Filtration of Isolated Particles From Plasma
When apoA-IV-containing particles were separated by gel filtration chromatography, distinct size subpop- A-IVLp, specifically bound apolipoprotein A-IV particles; LpA-I:A-IV, lipoproteins with apolipoproteins A-I and A-IV; LpA-IV, lipoproteins with apolipoprotein A-IV only.
•Subjects 1-5. (Figure 3 ). In the subpopulation of 10.3 nm, strong bands corresponding to apoA-I, apoD, and apoH were observed, along with some apoA-II. In the subpopulation of 9.3 nm, only apoA-I was visualized in addition to apoA-IV. As expected, apoA-I was found in these three fractions of A-IVLp because identical peaks were found in LpA-I:A-IV.
Cholesterol Efflux From Cholesterol-Preloaded
Ob 1771 Cells Incubation of [ 3 H]cholesterol-preloaded adipose cells with LpA-IV and LpA-I: A-IV promoted a cholesterol efflux from cells, whereas no efflux was promoted by the control DMPC liposomes (Table 3 ). There was a trend toward greater cholesterol efflux promotion by LpA-IV, but the two were not statistically different (nonparametric Wilcoxon test).
LCATand CET Activities of Isolated Particles From Plasma
Incubation of LpA-I: A-IV and LpA-IV with reconstituted [ protein particle per hour. These results showed that both particles have the potential to esterify cholesterol and the capacity to transfer it to a cholesterol acceptor. Discussion We describe here the characterization of apoA-IVcontaining lipoprotein particles from human plasma and interstitial fluid. Given the poor lipid-binding capability of human apoA-IV, our aim was to isolate native particles while minimizing the possibility of dissociation of this apolipoprotein. We used immunoaffinity chromatography with affinity-purified polyclonal antibodies against human apoA-IV.
ApoA-IV-containing particles that were isolated from human plasma and interstitial fluid were found to have a low lipid to protein ratio compared with apoA-I-containing particles.37 No significant differences were observed between A-IVLp isolated from human plasma and from interstitial fluid. This result indicates that the A-IVLp composition is similar in these two compartments. The high triglyceride content of the apoA-IVcontaining lipoprotein particles compared with the apoA-I-containing lipoprotein particles36J7 is consistent with the intestinal origin of human apoA-IV1 and the correlation between plasma levels of apoA-IV and triglycerides.38 Although apoA-IV is the principal apolipoprotein of the A-IVLp particles, other proteins were also detected on SDS-PAGE. A protein band of 59 kd was associated with the A-IVLp particles. A similar protein was first described in association with apoA-IV in rat chylomicrons39 and was also identified in the apoA-IV-containing fraction that was isolated from human plasma by Ohta et aL40 In the latter study, apoH was also found in association with apoA-IV. As the observed particle sizes of apoA-IV-containing particles are not large enough to accommodate even a single copy of all of these proteins, apoA-IV-containing particles must be heterogeneous. Moreover, the distribution of apoA-IV in plasma must be more complex, as apoA-IV is also associated with apolipoproteins in subclasses other than the HDL and VLDL subfractions.
When the A-IVLp particles were applied to the anti-apoA-I immunosorbent, 70% of the total protein in the particles was not retained by the immunosorbent. This fraction, referred to as the LpA-IV particle, contains mainly apoA-IV. This result disagrees with the data from Malmendier et a141 and Lagrost et a1,lO who found that the majority of apoA-IV was associated with apoA-I. This difference may be partially explained by the preparation of antibodies used for isolation. Our antibodies against apoA-IV were affinity purified and were passed through an apoA-I immunosorbent to remove antibodies that could recognize apoA-I as well as apoA-IV. Furthermore, when plasma aliquots were directly applied to an anti-apoA-I immunosorbent, only 5.8% of the total apoA-IV was retained by the immunosorbent. This result is in agreement with the apoA-IV proportion in the two A-IVLp subpopulations, LpA-IV and LpA-I : A-IV. The apolipoprotein molar ratio in LpA-1:A-IV is approximately 7 apoA-I, 2 apoA-11, and 1 apoA-IV. The LpA-1:A-IV may be a mixture of apoA-I-and apoA-IV-containing particles and of apoA-I-, apoA-11-, and apoA-IV-containing particles.
ApoA-IV-containing lipoprotein particles isolated from plasma are heterogeneous in size. All consist of two major populations, a larger one with a Stokes' diameter of 10.3 nm and a smaller one with a Stokes' diameter of 9.3 nm. These two apoA-IV-containing particle subpopulations have a distinct apolipoprotein composition. In A-IVLp, the presence of apoA-IV in each subpopulation and also apoA-I, apoA-11, apoD, or apoH was confirmed by using specific antibodies. Further investigation is required to understand the compo-sition and metabolic effects of the subpopulations of apoA-IV-containing lipoprotein particles.
LpA-I:A-IV and LpA-IV particles are effective in promoting cholesterol efflux from cholesterol-preloaded adipose cells as well as is A-IVLp. 17 In all three particle subpopulations, the content (on a molar basis) of apoA-II, however, is too far outnumbered by apoA-I and/or apoA-IV. Thus, the apoA-II in these apoA-IV-containing particles may not exert its inhibitory function on cholesterol efflux at this concentration and molar ratio. 42 LpA-I:A-IV and LpA-IV particles also contain LCAT and CET activities. ApoA-IV-containing particles exist in high levels in human interstitial fluid. 3 The lipid and protein composition of apoA-IV-containing particles that have been isolated from interstitial fluid seems to be similar to that of apoA-IV-containing particles that have been isolated from plasma.
ApoA-IV-containing particles have a different composition than apoA-I-containing particles 37 but have several common physiological properties, i.e., they promote cholesterol efflux from adipose cells and have LCAT and CET activities. Thus, apoA-IV-containing particles may serve as a "surrogate" for apoA-I-containing particles in promoting reverse cholesterol transport in conditions characterized by a low plasma apoA-I level without premature coronary heart disease, such as Tangier disease, 43 LCAT deficiency, and fish eye disease 44 and apoA-I mutations. 45 ' 46 
